MASITINIB Trial – February 2012

On 1ST February AB Science published a press release announcing encouraging results from a phase2 trial of their drug masitinib. The trial compared masitinib vs sunitinib for the second-line treatment of patients with locally advanced or metastatic imatinib-resistant GIST. Members of SPAEN and clinical experts felt at the time that AB Science’s claims were premature. However subsequent information about Masitinib is more encouraging, although it may be some time before it is available in the UK. Click here  to see the full text of the press release and SPAEN’s critique.

Posted in GIST News.